Europa are delighted to link with I3E and look forward to early September Serenity appraisal spud. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

IN BRIEF: Malin's Poseida Therapeutics signs agreement with Roche

Fri, 5th Aug 2022 19:38

Malin Corp PLC - Dublin-based investor in life sciences companies - Notes announcement from Nasdaq-listed Poseida Therapeutics Inc of its entry into a strategic collaboration and licence agreement with Roche Holding AG, for the development of allogeneic CAR-T therapies directed towards hematologic malignancies.

Poseida will receive USD110 million upfront, and can fain an additional USD110 million in near-term milestones and other payments.

Current stock price: EUR4.15

12-month change: down 38%

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Related Shares

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.